F072 The Morbilliform Eruption: Differentiation and Treatment of Viral, Low-risk Drug, Severe Cutaneous Adverse Reactions, and GVHD
DESCRIPTION
The morbilliform eruption is the most common cutaneous morphology encountered in the hospital setting. Despite its frequency, there is a dearth of literature and lectureships available to support evidenced-based guidelines especially for the early identification of disease etiology. This session will focus on the early and accurate diagnosis and differentiation of low-risk drug eruptions, severe cutaneous adverse reactions, viral eruptions, and GVHD in the adult patient.
LEARNING OBJECTIVES
Identify distinguishing characteristics that allow differentiation of morbilliform eruptions into high-risk and low-risk categories
Differentiate early severe cutaneous adverse reactions by morphologic differences, followed by confirmatory testing
Recognize laboratory testing and algorithms available to support the diagnosis of drug eruptions, viral reactions, and Graft-Versus-Host Disease.
SCHEDULE
3:30 PM
Welcome, Introduction, and Differentiating High-Risk from Low-Risk Morbilliform Reactions
Benjamin Kaffenberger, MD, FAAD
3:50 PM
Differentiation of Severe Cutaneous Adverse Reactions
Lauren Michelle Madigan, MD, FAAD
4:10 PM
Differentiation of Acute Graft-Versus-Host Disease
Brittany L Dulmage, MD, FAAD
4:25 PM
Morbilliform reactions to Immunotherapy
Nima Milani-Nejad, MD, PhD, FAAD
4:40 PM
Clinicopathologic Correlation in Morbilliform Reactions
Catherine Chung, MD, FAAD
4:55 PM
Morbilliform Reactions in Patients of Color
Tejesh Patel, MD, FAAD
5:10 PM
Treatment of Severe Cutaneous Adverse Reactions and Morbilliform Reactions
5:25 PM
Question and Answer Session
DIRECTOR
Benjamin Kaffenberger, MD, FAAD
SPEAKERS
Catherine Chung, MD, FAAD
Brittany L Dulmage, MD, FAAD
Lauren Michelle Madigan, MD, FAAD
Nima Milani-Nejad, MD, PhD, FAAD
Tejesh Patel, MD, FAAD
HANDOUTS
DISCLOSURES
Catherine Chung, MD, FAAD
No financial relationships exist with ineligible companies.
Brittany L Dulmage, MD, FAAD
Hoth Therapeutics – Data Safety Monitoring Board(Honoraria); Novocure – Consultant (1099 relationship)(Honoraria);
Benjamin Kaffenberger, MD, FAAD
ADC Therapeutics – Consultant (1099 relationship)(Fees); Biogen – Investigator(Grants/Research Funding); Bristol-Myers Squibb – Investigator(Grants/Research Funding); Dermatology Foundation – Investigator(Grants/Research Funding); Eli Lilly and Company – Consultant (1099 relationship)(Honoraria); Elsevier Inc. – Consultant(Honoraria); InflaRx – Investigator(Grants/Research Funding); Merck – Investigator(Grants/Research Funding); National Comprehensive Cancer Network – Speaker(Honoraria); National Psoriasis Foundation – Investigator(Grants/Research Funding); Novartis – Consultant(Honoraria); Novocure – Consultant(Honoraria); OnQuality Pharmaceuticals, Ltd. – Investigator(Grants/Research Funding);
Lauren Michelle Madigan, MD, FAAD
No financial relationships exist with ineligible companies.
Nima Milani-Nejad, MD, PhD, FAAD
No financial relationships exist with ineligible companies.
Tejesh Patel, MD, FAAD
Dermeleve – Advisory Board(Other Financial Benefit); Foundation for Research & Education of Dermatology – Speaker(Honoraria);